Company profile
BriaCell Therapeutics Corp.
NASDAQ: BCTX · Healthcare · Biotechnology
Canadian filerHQ West Vancouver, BCCIK 0001610820Reports USD
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH 30DQ —GM —SS 51
v0.1 · 35/100 weight · pillars only
↑ filing timeliness, listing tenure · ↓ Piotroski F, return on assets
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$26.3M
Employees
16
as of 2026-08-23
Market cap
$35.4M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$26.3M-$26.3M2025
Operating income-$27.2M-$27.2M2025
Total assets$21.6M$21.6M2025
Equity$17.3M$17.3M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is BriaCell Therapeutics Corp.’s financial profile?
BriaCell Therapeutics Corp. earned -$26.3M in FY2025 net income.
Peers · Healthcare
Cell Source, Inc.——Rocket Doctor AI Inc.——BetterLife Pharma Inc.——Obsidian Therapeutics Inc.——MIRA Pharmaceuticals, Inc.——Lantern Pharma Inc.——Key facts
CEOWilliam V. Williams
SectorHealthcare
IndustryBiotechnology
HeadquartersWest Vancouver, BC
ExchangeNASDAQ: BCTX
Employees16
IPO date2012-03-14
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.